As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B ...

Hospital groups raise issues with 340B rebate pilot program citing cash flow, administrative costs, and unclear rebate denials risks.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

In Washington, D.C., lawmakers are engaged in marathon talks about how to reduce health care costs. There haven’t been any ...

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

In a letter last week, Johnson & Johnson informed certain hospitals of a major change it plans to make in the way it gives out discounts on two drugs. The company has found itself in opposition to ...

The 340B Drug Pricing Program was created in 1992 and allows hospitals and clinics that treat a large population of low-income and uninsured patients to buy outpatient prescription drugs at a discount ...

The 340B Drug Pricing Program (340B) is a cornerstone of equitable healthcare in the U.S. For more than 30 years, it has ensured that drug manufacturers provide discounted medications to qualifying ...

The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...